BIOMAT Database Logo BIOMAT Database Logo

Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas. 2024

Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China.

The conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma (NHL). A total of 141 NHL patients received AD-BEAC or a standard-dose BEAC (SD-BEAC) conditioning regimen from January 2007 to December 2017, and 104 patients were included in the study after 1:1 propensity matching. The 5-year overall survival (OS) and progression free survival (PFS) rates were significantly higher with AD-BEAC than with SD-BEAC (82.7% vs. 67.3%, P = 0.039; 76.9% vs. 57.7%, P = 0.039). Transplant-related mortality (TRM) was 3.8% in both the AD-BEAC and SD-BEAC groups. The AD-BEAC group had lower incidence of oral ulcers and cardiotoxicity than the SD-BEAC group. An optimized BEAC conditioning regimen is an effective conditioning regimen for ASCT in NHL with acceptable toxicity, that is more effective and safer than a standard BEAC conditioning regimen.

UI MeSH Term Description Entries

Related Publications

Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
June 2019, Bone marrow transplantation,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
January 2024, Cancer medicine,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma.
March 2018, International journal of hematologic oncology,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
October 2019, Bone marrow transplantation,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas.
January 2005, Acta haematologica,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial.
June 2023, Chinese medical journal,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
[Autologous stem cell transplantations in non-Hodgkin lymphomas].
January 2001, Duodecim; laaketieteellinen aikakauskirja,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation].
September 2021, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.
October 2017, Asia-Pacific journal of clinical oncology,
Sha Zhou, and Jun Rao, and Xiangyu Ma, and Yunjing Zeng, and Xixi Xiang, and Jiali Li, and Hongyun Liu, and Shijia Lin, and Song Dong, and Fu Li, and Xi Zhang, and Li Gao
Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
November 2023, Bone marrow transplantation,
Copied contents to your clipboard!